MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Thomas Biegi News
Page 8 - Thomas Biegi News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Thomas Biegi. Real-time updates on events, politics, business and more.
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys AG / Key word(s): Agreement MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felza...
Source: businessinsider.com
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib-relapsed/refractory patients A comparative model suggests
Source: finanznachrichten.de
MorphoSys AG Reports Outcome of Annual General Meeting 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company's Management and Supervisory
Source: finanznachrichten.de
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: MorphoSys AG / Key word(s): AGM/EGM MorphoSys AG Reports Outcome of Annual General Meeting 2022 18.05.2022 / 22:02 ...
Source: businessinsider.com
MorphoSys AG: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST (9:00 pm GMT; 4:00 pm EDT).MorphoSys'
Source: finanznachrichten.de
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
DGAP-News: MorphoSys AG / Key word: Quarter Results Invitation to MorphoSys First Quarter 2022 Financial Results Conference Call on May 5, 2022 28.04.2022 / 22:03 The issuer...
Source: marketscreener.com
MorphoSys AG: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell LymphomaMinjuvi
Source: finanznachrichten.de
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Monjuvi U.S. net product sales of US$ 23.6 million (€ 20.5 million) for the fourth quarter and US$ 79.1 million (€ 66.9 million) for the full year 2021 Pipeline advances: enrollment progressing across
Source: finanznachrichten.de
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
DGAP-News: MorphoSys AG / Key word: Annual Report MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update 16.03.2022 / 21:01 The... | March 16, 2022
Source: marketscreener.com